NASDAQ:ARWR   Arrowhead Pharmaceuticals, Inc.
This has completed W2 correction and found support at the 38% FR


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.